Occam Places Chief Legal Officer at Public Oncology Biotech
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company focused on the development and commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. In August 2023, Occam placed Scott Samuels as SVP, Chief Legal Officer, and Corporate Secretary.
Prior to Geron, Scott served as Chief Legal and Compliance Officer of clinical-stage biotech, Prilenia Therapeutics. He was formerly the founding General Counsel of BeiGene, where he strategically built the company’s legal and compliance functions. Scott began his operating career at ARIAD after 17 years spent in the corporate and life sciences practices of Mintz Levin. Scott holds a J.D. from George Mason University and a B.A. in philosophy from Cornell University.
Geron is a longstanding client for whom Occam has previously placed three independent Board members, John, McDonald, Dawn Bir, and Liz O'Farrell, and more recently, Chief Business Officer Edward Koval and VP Investor Relations & Corporate Communications Aron Feingold.
Related Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.